The development of third‐generation EGFR tyrosine kinase inhibitors (EGFR‐TKIs), such as osimertinib (OSI) [5], marked a paradigm shift in treating EGFR mutation‐positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.